# Paltusotine

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/paltusotine
Canonical HTML page: https://getyourbrief.com/entity/paltusotine

## Timeline

- **2026-07**: Vertex announces $10 billion acquisition of Crinetics — Vertex Pharmaceuticals agrees to buy Crinetics Pharmaceuticals for $10 billion in cash, gaining a pipeline of endocrine therapies; the deal has not yet closed.

## Recent coverage (4 stories, network-wide)

### VKTX Stock: The $10B Vertex-Crinetics Deal Warms Up a $20B Viking Takeover
2026-07-31 06:15:41 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2

Vertex's $10B cash acquisition of Crinetics sets a powerful precedent, suggesting Viking Therapeutics could command a $15–20B price tag in a consolidating obesity market. For investors, VKTX's late-stage pipeline and the appetite of cash-rich pharma giants offer a high-risk, high-reward M&A setup.
Full story: https://getfinancebrief.com/story/viking-therapeutics-stock-vertex-crinetics-acquisition-finance

### Viking's $190B Obesity Pipeline Beckons: Could It Be the Next $10B Biotech Buyout?
2026-07-31 06:14:04 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Vertex's $10B buyout of Crinetics highlights the frenzied demand for metabolic pipelines. Viking Therapeutics, with a Phase 3 obesity asset and an oral candidate nearing late-stage trials, now looks like the most logical next takeover target in the rapidly expanding $190B weight-loss market.
Full story: https://getbiobrief.com/story/viking-therapeutics-vertex-crinetics-obesity-acquisition-bio

### Crinetics (CRNX) Advances Toward Commercialization Amid Q4 2025 Earnings Wave
2026-02-27 01:35:34 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Crinetics Pharmaceuticals (CRNX) reported Q4 2025 results, highlighting critical progress in its endocrine pipeline and preparations for the commercial launch of paltusotine. Alongside results from MDxHealth and Baldwin, the earnings cluster reflects a strategic transition for mid-cap healthcare and service firms navigating the 2026 market landscape.
Full story: https://getfinancebrief.com/story/crinetics-crnx-q4-2025-earnings-analysis

### Q4 2025 Earnings: Precision Diagnostics and Endocrine Innovation Drive Growth
2026-02-27 01:33:26 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 3

The Q4 2025 earnings reports from Crinetics, MDxHealth, and Baldwin highlight a pivotal shift toward precision diagnostics and specialized endocrine therapies. These results underscore a robust recovery in diagnostic volumes and a maturing pipeline for rare disease treatments entering commercialization phases.
Full story: https://gethealthbrief.com/story/q4-2025-healthcare-earnings-crinetics-mdxhealth-baldwin

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.